LBF20307PG38: Difference between revisions

No edit summary
No edit summary
 
(7 intermediate revisions by the same user not shown)
Line 6: Line 6:
|LipidBank=XPR1901
|LipidBank=XPR1901
|LipidMaps=LMFA03010019
|LipidMaps=LMFA03010019
|SysName=7- [ 2 (R) - (3 (S) -Hydroxy-1 (E) -octenyl) -3-oxo-4-cyclopenten-1 (R) -yl ] -5 (Z) -heptenoic acid
|SysName=7- [2R- (3S-hydroxy-trans-1-octenyl) -3-oxo-4-cyclopenten-1R-yl] -cis-5-heptenoic acid
|Common Name=&&PROSTAGLANDIN J_2&&
|Common Name=&&Prostaglandin J_2&&7- [2R- (3S-Hydroxy-1-(E)-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5-(Z)-heptenoic acid&&
|Solubility=ACETONITRILE<!--1048-->, CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
|Solubility=ACETONITRILE<!--以下1048-->[[Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093|
{{RelationTable/GetFirstAuthor|Reference:Mubarik-Ali_S:Chapeleo_CB:Finch_MAW:Roberts_SM:Woolley_GT:Cave_RJ:and Newton_RF:,J. Chem. Soc.,1980,,2093}}]], CHLOROFORM, ETHANOL [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
|Mass Spectra=TMS ETHER ; M^+  478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
|Mass Spectra=TMS ETHER ; M^+  478.2934 [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
|UV Spectra= lambda  ^{MeOH}_{max} = 305( epsilon  1200), 216( epsilon  9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
|UV Spectra= lambda  ^{MeOH}_{max} = 305( epsilon  1200), 216( epsilon  9900)nm [[Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790|{{RelationTable/GetFirstAuthor|Reference:Bundy_GL:Morton_DR:Peterson_DC:Nishizawa_EE:Miller_WL:,J. Med. Chem.,1983,26,790}}]]
Line 18: Line 19:
|Symbol=PGJ2
|Symbol=PGJ2
|Biological Activity=The anti-tumor and anti-viral activities of prostaglandin J2 are attributed to  Delta 12-prostaglandin J2 which is a degradation product of prostagladnin J2 and is characteristic of its alkylidene cyclopentenone structure [[Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1|{{RelationTable/GetFirstAuthor|Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1}}]].
|Biological Activity=The anti-tumor and anti-viral activities of prostaglandin J2 are attributed to  Delta 12-prostaglandin J2 which is a degradation product of prostagladnin J2 and is characteristic of its alkylidene cyclopentenone structure [[Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1|{{RelationTable/GetFirstAuthor|Reference:Fukushima_M:,Prostaglandins Leukot. Essent. Fatty Acids,1992,47,1}}]].
}}
{{MassbankSpectra|
UT000361
UT000362
UT000363
UT000364
UT000365
UT000366
UT000367
UT000368
UT000369
}}
}}


{{Lipid/Footer}}
{{Lipid/Footer}}

Latest revision as of 00:00, 17 January 2014

LipidBank Top
(トップ) 		Fatty acid
(脂肪酸) 		Glycerolipid
(グリセロ脂質) 		Sphingolipid
(スフィンゴ脂質) 		Journals
(雑誌一覧) 		How to edit
(ページの書き方)


Upper classes: LB LBF



IDs and Links
LipidBank XPR1901
LipidMaps LMFA03010019
CAS
KEGG {{{KEGG}}}
KNApSAcK {{{KNApSAcK}}}
mol LBF20307PG38
Prostaglandin J2
LBF20307PG38.png
Structural Information
7- [2R- (3S-hydroxy-trans-1-octenyl) -3-oxo-4-cyclopenten-1R-yl] -cis-5-heptenoic acid
  • Prostaglandin J2
  • 7- [2R- (3S-Hydroxy-1-(E)-octenyl) -3-oxo-4-cyclopenten-1R-yl] -5-(Z)-heptenoic acid
 PGJ2
Formula C20H30O4
Exact Mass 334.21440944799997
Average Mass 334.4498
SMILES C(CC[C@@H](O)C=C[C@@H](C(=O)1)[C@@H](CC=CCCCC(O)=O)C=C1)CC
Physicochemical Information
ACETONITRILE Mubarik-AliSet al., CHLOROFORM, ETHANOL Bundy_GL et al.
Bundy_GL et al.
LBF20307PG38FT0001.gif
 In aqueous solution prostaglandin D2 undergoes non-enzymatic dehydration and is converted to prostaglandin J2 Fukushima_M .
The anti-tumor and anti-viral activities of prostaglandin J2 are attributed to Delta 12-prostaglandin J2 which is a degradation product of prostagladnin J2 and is characteristic of its alkylidene cyclopentenone structure Fukushima_M .
Spectral Information
Mass Spectra TMS ETHER ; M+ 478.2934 Bundy_GL et al.
UV Spectra λ MeOH
max     = 305( ε 1200), 216( ε 9900)nm Bundy_GL et al.
IR Spectra ν 3400, 3200, 2660, 1710, 1085, 970 cm-1 Bundy_GL et al.
NMR Spectra 1H-NMR(CDCl3) : δ 7.75-7.55(m, 1H, 9-CH), 6.30-6.10(m, 1H, 10-CH), 5.90(brs, 2H, OH), 5.75-5.35(m, 4H), 4.30-3.95(m, 1H, 15-CH) Bundy_GL et al.
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20307PG38 See above. Bundy_GL et al. 1983
n.a. LBF20307PG38 See above. Fukushima_M 1992
n.a. LBF20307PG38 See above. Mubarik-Ali_S et al. 1980



Retrieved from "http://lipidbank.jp/mediawiki/index.php?title=LBF20307PG38&oldid=81364"